Overview

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

Status:
Completed
Trial end date:
1999-02-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.
Phase:
Phase 3
Details
Lead Sponsor:
National Center for Research Resources (NCRR)
Collaborator:
University of Tennessee
Treatments:
Mexiletine